Flu Forecast and Synthetic Vaccines


Home
Overview
Videos
Background
The Science
Contact Us
Replikins Press

Overview

Replikins, Ltd. develops and markets novel forecasting tools and synthetic vaccines to fight virulent rapidly replicating diseases including bird flu, malaria, and HIV. The company's predictive products and vaccines in development are based upon the company's discovery of Replikins, a new group of peptides related to the rapid replication function in viral and other diseases. The company has designed unique products to predict the emergence of virulent strains of particular diseases (FluForecast™) and is designing synthetic vaccines specifically tailored to combat a given strain and against shared properties of several strains (Syntope™ vaccines). The company is partnering with governments and the private sector in providing predictive tools and vaccines in furtherance of the public health initiative to prevent and combat epidemics.
To date, no means has been available to predict if and what strain of a given organism will threaten a human or animal population. It has not been possible to design appropriate vaccines, produce, test and administer them before an epidemic has emerged and caused damage to a population. Replikins, Ltd's predictive FluForecast™ product enables advance warning of potential epidemics. The company's understanding of the protein chemistry of rapid replication has also enabled it to design synthetic vaccines specifically tailored to destroy or restrict replication of the targeted virus strains before an outbreak. The vaccines are currently in development.
The company's vaccines and predictive tools are based on the company's discovery of a new group of peptides responsible for rapid replication called Replikins, whose increase in concentration in virus or other organism proteins (Replikin Count™ peptide quantities) is associated with rapid replication. By tracing the Replikin Count™ peptide quantities, epidemics can be predicted earlier (one to three years in advance) and it is the company's goal to design, test and prepare for administration synthetic vaccines prior to the outbreak of those epidemics

Recent Press

Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased Boston, November 27, 2009 - Biotech firm Replikins Ltd., which has analyzed the H1N1 virus' genomic data from the 1918 pandemic through the prediction, outbreak, and progress of the current H1N1 pandemic, today issued its latest biochemical analysis of the virus... Read more
New Non-Biological Synthetic Replikins™ Vaccines Shown to Be Effective and Fast; WorldVaccines™, Ltd. Formed for Testing and Distribution Old Biological Vaccines for Emergent Diseases - Too Little, Too Late Boston, October 19, 2009 - There is increasing evidence that, with best intent, current biological technology cannot supply the world's six billion humans, and animal populations, with vaccines against emerging diseases at a rate that can contend with a disease's rapid appearance and change... Read more